This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at: https://awmsg.nhs.wales/.
awmsg logo



ceftolozane/tazobactam (Zerbaxa®)


Reference No. 2182

Publication date:
18/02/2020


Appraisal information

ceftolozane/tazobactam (Zerbaxa®) 1 g/0.5 g powder for concentrate for solution for infusion


Company: Merck Sharp & Dohme Ltd
BNF category: Infections
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 10/02/2020

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, ceftolozane/tazobactam (Zerbaxa®) cannot be endorsed for use within NHS Wales for the treatment of hospital-acquired pneumonia, including ventilator‑associated pneumonia in adults
Statement of Advice (SOA)
Download